In the case of MOv18 IgE, this limitation may be overcome by the kinetic properties of this antibody class: once engaged with FcεRI-expressing immune effector cells, MOv18 IgE may be trafficked away from the circulation into the tumour where the majority of FRα may be present on the target tumour cells rather than in soluble form. Here, IGHE is linked to neoplasm.